Monte Rosa Therapeutics: Roche Partnership Deal Could Bring Added Value (NASDAQ:GLUE)
JazzIRT/iStock via Getty Images Monte Rosa Therapeutics (NASDAQ:GLUE) has been making good progress in advancing its pipeline of molecular glue degraders [MGDs]. The goal is to have protein-to-protein interaction to eliminate diseases but without binding pockets. Such an approach allows it to go after target indications that are thought to be undruggable with other small…